ENTRY       D10831                      Drug
NAME        Susoctocog alfa (INN);
            Susoctocog alfa (genetical recombination) (JAN);
            Obizur (TN)
SEQUENCE    AIRRYYLGAV ELSWDYRQSE LLRELHVDTR FPATAPGALP LGPSVLYKKT VFVEFTDQLF
            SVARPRPPWM GLLGPTIQAE VYDTVVVTLK NMASHPVSLH AVGVSFWKSS EGAEYEDHTS
            QREKEDDKVL PGKSQTYVWQ VLKENGPTAS DPPCLTYSYL SHVDLVKDLN SGLIGALLVC
            REGSLTRERT QNLHEFVLLF AVFDEGKSWH SARNDSWTRA MDPAPARAQP AMHTVNGYVN
            RSLPGLIGCH KKSVYWHVIG MGTSPEVHSI FLEGHTFLVR HHRQASLEIS PLTFLTAQTF
            LMDLGQFLLF CHISSHHHGG MEAHVRVESC AEEPQLRRKA DEEEDYDDNL YDSDMDVVRL
            DGDDVSPFIQ IRSVAKKHPK TWVHYISAEE EDWDYAPAVP SPSDRSYKSL YLNSGPQRIG
            RKYKKARFVA YTDVTFKTRK AIPYESGILG PLLYGEVGDT LLIIFKNKAS RPYNIYPHGI
            TDVSALHPGR LLKGWKHLKD MPILPGETFK YKWTVTVEDG PTKSDPRCLT RYYSSSINLE
            KDLASGLIGP LLICYKESVD QRGNQMMSDK RNVILFSVFD ENQSWYLAEN IQRFLPNPDG
            LQPQDPEFQA SNIMHSINGY VFDSLQLSVC LHEVAYWYIL SVGAQTDFLS VFFSGYTFKH
            KMVYEDTLTL FPFSGETVFM SMENPGLWVL GCHNSDLRNR GMTALLKVYS CDRDIGDYYD
            NTYEDIPGFL LSGKNVIEPR SFAQNSRPPS ASAPKPPVLR RHQRDISLPT FQPEEDKMDY
            DDIFSTETKG EDFDIYGEDE NQDPRSFQKR TRHYFIAAVE QLWDYGMSES PRALRNRAQN
            GEVPRFKKVV FREFADGSFT QPSYRGELNK HLGLLGPYIR AEVEDNIMVT FKNQASRPYS
            FYSSLISYPD DQEQGAEPRH NFVQPNETRT YFWKVQHHMA PTEDEFDCKA WAYFSDVDLE
            KDVHSGLIGP LLICRANTLN AAHGRQVTVQ EFALFFTIFD ETKSWYFTEN VERNCRAPCH
            LQMEDPTLKE NYRFHAINGY VMDTLPGLVM AQNQRIRWYL LSMGSNENIH SIHFSGHVFS
            VRKKEEYKMA VYNLYPGVFE TVEMLPSKVG IWRIECLIGE HLQAGMSTTF LVYSKECQAP
            LGMASGRIRD FQITASGQYG QWAPKLARLH YSGSINAWST KDPHSWIKVD LLAPMIIHGI
            MTQGARQKFS SLYISQFIIM YSLDGRNWQS YRGNSTGTLM VFFGNVDASG IKHNIFNPPI
            VARYIRLHPT HYSIRSTLRM ELMGCDLNSC SMPLGMQNKA ISDSQITASS HLSNIFATWS
            PSQARLHLQG RTNAWRPRVS SAEEWLQVDL QKTVKVTGIT TQGVKSLLSS MYVKEFLVSS
            SQDGRRWTLF LQDGHTKVFQ GNQDSSTPVV NALDPPLFTR YLRIHPTSWA QHIALRLEVL
            GCEAQDLY
            (Disulfide bridge: 154-180, 249-330, 528-554, 630-711, 948-974, 1015-1019, 1137-1285, 1290-1442)
  TYPE      Peptide
CLASS       Blood modifier agent
             DG02016  Hemostatics
              DG02014  Blood coagulation accelerant
               DG02013  Blood coagulation factor
REMARK      ATC code: B02BD02
            Chemical structure group: DG00170
            Product (DG00170): D08798<JP> D05409<JP> D10227<JP> D10539<JP> D10758<JP> D10759<JP> D10760<JP> D10771<JP> D10818<JP> D10842<JP>
EFFICACY    Bleeding suppressant
COMMENT     Therapeutic area: Hemophilia A
INTERACTION  
BRITE       Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
             B BLOOD AND BLOOD FORMING ORGANS
              B02 ANTIHEMORRHAGICS
               B02B VITAMIN K AND OTHER HEMOSTATICS
                B02BD Blood coagulation factors
                 B02BD02 Coagulation factor VIII
                  D10831  Susoctocog alfa (INN)
            Drug groups [BR:br08330]
             Blood modifier agent
              DG02016  Hemostatics
               DG02014  Blood coagulation accelerant
                DG02013  Blood coagulation factor
                 DG00170  Blood coagulation factor VIII
                  D10831  Susoctocog alfa
            New drug approvals in Europe [br08329.html]
             European public assessment reports (EPAR) authorised medicine
              D10831
            Drug groups [BR:br08330]
             Blood modifier agent
              DG02016  Hemostatics
               DG02014  Blood coagulation accelerant
                DG02013  Blood coagulation factor
                 DG00170  Blood coagulation factor VIII
DBLINKS     CAS: 1339940-90-7
            PubChem: 319902631
///
